Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials.
about
Emerging drugs for Guillain-Barré syndromeIntravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathyIntravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathyPrecision medicine in myasthenia graves: begin from the data precisionConstruction and validation of the chronic acquired polyneuropathy patient-reported index (CAP-PRI): A disease-specific, health-related quality-of-life instrument.Quality of life and measures of quality of life in patients with neuromuscular disorders.The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.Molecularly targeted therapies for dysimmune neuropathiesNeuromuscular issues in systemic disease.Progress in inflammatory neuropathy -the legacy of Dr Jack Griffin.Correlation of the patient's reported outcome Inflammatory-RODS with an objective metric in immune-mediated neuropathies.Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MMN-RODS(©) ).Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparison.Validity of the shuttle walk test as a functional assessment of walking ability in individuals with polyneuropathy.Outcome measures in MMN revisited: further improvement needed.Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel.
P2860
Q22241376-D735C40F-95E6-4E6E-A4ED-DE75C9D9540EQ24201573-D85F311D-66E0-4002-8E6E-B83CC503C335Q24240936-6F13B3C1-369F-42C6-87B6-6B9F4B194991Q26748943-5531689C-F5C8-4990-87DC-D2953C060893Q30278029-E2CE4C55-BC87-4D00-A40B-B20EFF45FA47Q30455590-6E6B8CA7-8979-423A-8121-A12A3DA8DA1CQ36551631-06C17C3E-57BF-452C-82FD-CFDA6D3BC348Q37254545-C53BD8D6-A1E3-4860-B35A-4AECAF4ECF20Q38501865-8ECEAD22-8F10-4D67-8D94-D25012E56E92Q38605062-D39E473F-92FC-4C96-9229-55729F06E83FQ38873864-FD6E1EC1-26A4-493C-B31E-E229BA8CFD3EQ38968456-1752C9A1-48FC-4BD5-B663-2572467CA084Q38991147-67431F8B-4EB0-4F51-9B9C-4BBA8BB9925EQ40593249-4D6EC1CF-7D99-444C-94DE-63F64E900D6CQ40793045-39CC300A-30F2-4531-A279-6371A4F9580EQ48696185-441CF405-88A7-4ED0-A5B0-FC4E899F0E59
P2860
Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Outcome measures in immune-med ...... nd the clinimetric essentials.
@en
Outcome measures in immune-med ...... nd the clinimetric essentials.
@nl
type
label
Outcome measures in immune-med ...... nd the clinimetric essentials.
@en
Outcome measures in immune-med ...... nd the clinimetric essentials.
@nl
prefLabel
Outcome measures in immune-med ...... nd the clinimetric essentials.
@en
Outcome measures in immune-med ...... nd the clinimetric essentials.
@nl
P2860
P1476
Outcome measures in immune-med ...... and the clinimetric essentials
@en
P2093
Ingemar S J Merkies
Sonja I van Nes
P2860
P304
P356
10.1111/J.1529-8027.2008.00169.X
P577
2008-06-01T00:00:00Z